Akeso Inc
HKEX:9926

Watchlist Manager
Akeso Inc Logo
Akeso Inc
HKEX:9926
Watchlist
Price: 59.9 HKD -1.56% Market Closed
Market Cap: 53.8B HKD
Have any thoughts about
Akeso Inc?
Write Note

Gross Margin
Akeso Inc

92.2%
Current
91%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
92.2%
=
Gross Profit
1.7B
/
Revenue
1.9B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
CN
Akeso Inc
HKEX:9926
51.2B HKD
92%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
134.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
35.7B EUR
89%
Country CN
Market Cap 51.2B HKD
Gross Margin
92%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.3B USD
Gross Margin
67%
Country US
Market Cap 141.6B USD
Gross Margin
60%
Country US
Market Cap 115.3B USD
Gross Margin
78%
Country US
Market Cap 102.4B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 77.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 35.7B EUR
Gross Margin
89%
No Stocks Found

Akeso Inc
Glance View

Market Cap
51.9B HKD
Industry
Biotechnology

In the bustling landscape of biotechnology, Akeso Inc. emerges as a dynamic force addressing the dynamic and often daunting challenges of the medical world. Founded in 2012 and headquartered in China, this innovative company has made significant strides in the realm of biopharmaceuticals, particularly focusing on the research and development of novel therapies for oncology and immunology. Akeso Inc. differentiates itself through its comprehensive end-to-end approach, spanning discovery, clinical development, and commercialization. By leveraging its robust pipeline of therapeutic antibodies, the company constantly seeks to pioneer breakthroughs in cancer treatment and autoimmune disorders, thus driving its mission to enhance patient outcomes and address unmet medical needs. The economic engine of Akeso Inc. is driven by its ability to transform scientific research into viable therapeutic products. Revenue generation centers around the commercialization of their proprietary drugs, which often involves collaborations and strategic partnerships with major pharmaceutical players globally. These alliances not only expand the reach of Akeso's innovations but also provide essential capital and shared expertise that accelerate product advancement. The company's business model is further bolstered by licensing agreements and milestone payments, creating a steady stream of income as they navigate the rigorous pathways of drug approval and market entry. Through these ventures, Akeso Inc. not only secures its financial health but also continuously reinvests in its research endeavors, fueling a cycle of innovation that propels it forward in the competitive biotech arena.

Intrinsic Value
59.24 HKD
Overvaluation 1%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
92.2%
=
Gross Profit
1.7B
/
Revenue
1.9B
What is the Gross Margin of Akeso Inc?

Based on Akeso Inc's most recent financial statements, the company has Gross Margin of 92.2%.